21000 HPLC Kit Rufinamide Felbamate Lacosamide Serum Plasma

Rufinamide, Felbamate and Lacosamide in Serum/Plasma - HPLC

Order no.: 21000
100 Tests
  • Eslicarbazepine
  • Felbamate
  • Lacosamide
  • N-Desmethylmesuximide
  • Rufinamide

Rufinamide, Felbamate, Lacosamide, Eslicarbazepine, N-Desmethylmesuximide
No interference with concomitant drug therapy
Identical sample preparation to reagent kit order no. 22000
Option of combined analysis with 22000/F


Clinical relevance

Rufinamide, felbamate and mesuximide are approved in the EU for concomitant therapy in combination with other antiepileptic drugs (AEDs). They are primarily used to treat therapy-resistant epilepsies and Lennox–Gastaut syndrome, and are also suitable for difficult to treat epilepsies in children. Rufinamide and felbamate influence the effectiveness of other AEDs and contraceptive products. Eslicarbazepine acetate and lacosamide are also used in combination with other AEDs to treat partial epileptic seizures.

The blood levels of these medications must be determined to maintain the therapeutic range due to their pharmacodynamics and toxicities. That also includes measuring the levels of the metabolites N-desmethyl mesuximide and eslicarbazepine.


Product advantages

  • Undisturbed analysis for comedication with other antiepileptics
  • Sample preparation is identical to the reagent kit "Antiepileptics for HPLC", # 22000
  • Combined analysis with 22000/F is possible


Enhanced HPLC analysis of the antiepileptics enables the reliable determination of the AEDs rufinamide, felbamate, lacosamide, eslicarbazepine and N-desmethyl mesuximide. Sample preparation requires only one precipitation step and is identical to that of the Chromsystems kit # 22000. It has been tested for interference from other AEDs and can therefore guarantee undisturbed analysis even in the case of concomitant therapy with other AEDs.

Our Parameter Set Antiepileptics from the MassTox® Series A is available as an alternative for the measurement of these analytes with LC-MS/MS.


Technical Data

Method of Analysis


Number of Tests



Eslicarbazepine, Felbamate, Lacosamide, N-Desmethylmesuximide, Rufinamide

Analysis Time

< 15 min

Limit of quantification

0.5–1.0 mg/l


up to 200 mg/l


100 %


CV < 2 %


CV < 2 %



Pre-analytic Treatment

Patient samples are stable up to 4 weeks at +2 to +8 °C. For longer storage (up to 12 weeks) keep samples below -18 °C.

Sample Preparation

  • Pipette 100 µl serum/plasma and 150 µl Internal Standard into a reaction vial.
  • Mix 2 s (vortex).
  • Add 50 µl Precipitation Reagent.
  • Mix 1 min (vortex).
  • Centrifuge 10 min at 15000 x g.
  • Mix 100 µl supernatant with 100 µl Stabilisation Buffer.
  • Inject 20 µl into the HPLC system.

Sample Stability

At ambient temperature 1 week, at +2 to +8 °C 2 weeks and below -18 °C 3 weeks.

Additional Info

Isocratic HPLC system with UV detector.

Injection Volume

20 µl

Flow rate

2.5 ml/min



Column temperature

ambient temperature (~25 °C)


204 nm

Please note

The freely available information on this website, in particular on the sample preparation, are not sufficient to work with our products. Please read instructions and warning notices on products and/or instruction manuals.

Kit Components

Components available separately


Calibrators available separately


Controls available separately